Mostrar el registro sencillo del ítem

Artículo

dc.creatorVitorica Ferrández, Francisco Javieres
dc.creatorGonzález Domínguez, Raúles
dc.creatorGarcía Barrera, Tamaraes
dc.creatorGómez Ariza, José Luises
dc.date.accessioned2023-07-06T12:26:07Z
dc.date.available2023-07-06T12:26:07Z
dc.date.issued2015-01-05
dc.identifier.citationVitorica Ferrández, F.J., González Domínguez, R., García Barrera, T. y Gómez Ariza, J.L. (2015). Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer's disease by direct infusion mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 102, 425-435. https://doi.org/10.1016/j.jpba.2014.10.009.
dc.identifier.issn0731-7085es
dc.identifier.urihttps://hdl.handle.net/11441/147772
dc.description.abstractThe identification of pathological mechanisms underlying to Alzheimer's disease is of great importance for the discovery of potential markers for diagnosis and disease monitoring. In this study, we investigated regional metabolic alterations in brain from the APP/PS1 mice, a transgenic model that reproduces well some of the neuropathological and cognitive deficits observed in human Alzheimer's disease. For this purpose, hippocampus, cortex, cerebellum and olfactory bulbs were analyzed using a high-throughput metabolomic approach based on direct infusion mass spectrometry. Metabolic fingerprints showed significant differences between transgenic and wild-type mice in all brain tissues, being hippocampus and cortex the most affected regions. Alterations in numerous metabolites were detected including phospholipids, fatty acids, purine and pyrimidine metabolites, acylcarnitines, sterols and amino acids, among others. Furthermore, metabolic pathway analysis revealed important alterations in homeostasis of lipids, energy management, and metabolism of amino acids and nucleotides. Therefore, these findings demonstrate the potential of metabolomic screening and the use of transgenic models for understanding pathogenesis of Alzheimer's disease.es
dc.description.sponsorshipMinisterio de Ciencia e Innovación (MICIN). España CTM2012-38720-C03-01es
dc.description.sponsorshipJunta de Andalucía P008-FQM-3554; P009-FQM-4659es
dc.formatapplication/pdfes
dc.format.extent39 p.es
dc.language.isoenges
dc.publisherElsevieres
dc.relation.ispartofJournal of Pharmaceutical and Biomedical Analysis, 102, 425-435.
dc.subjectAlzheimer's diseasees
dc.subjectAPP/PS1 micees
dc.subjectBrain regionses
dc.subjectDirect infusion mass spectrometryes
dc.subjectMetabolomicses
dc.titleMetabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer's disease by direct infusion mass spectrometryes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/acceptedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Bioquímica y Biología Moleculares
dc.relation.projectIDCTM2012-38720-C03-01es
dc.relation.projectIDP008-FQM-3554es
dc.relation.projectIDP009-FQM-4659es
dc.relation.publisherversionhttps://doi.org/10.1016/j.jpba.2014.10.009es
dc.identifier.doi10.1016/j.jpba.2014.10.009es
dc.journaltitleJournal of Pharmaceutical and Biomedical Analysises
dc.publication.volumen102es
dc.publication.initialPage425es
dc.publication.endPage435es
dc.contributor.funderMinisterio de Ciencia e Innovación (MICIN). Españaes
dc.contributor.funderJunta de Andalucíaes

FicherosTamañoFormatoVerDescripción
Metabolomic_screening_of_ ...883.0KbIcon   [PDF] Ver/Abrir   Artículo

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Este documento está protegido por los derechos de propiedad intelectual e industrial. Sin perjuicio de las exenciones legales existentes, queda prohibida su reproducción, distribución, comunicación pública o transformación sin la autorización del titular de los derechos, a menos que se indique lo contrario.